About Sanifit
Sanifit: A Revolutionary Approach to Calcification Disorders
Sanifit is a biopharmaceutical company that is dedicated to developing innovative treatments for calcification disorders. The company was founded in 2007 by a team of experienced scientists and entrepreneurs who recognized the need for new therapies that could address the underlying causes of these debilitating conditions.
Calcification disorders are a group of diseases that are characterized by the abnormal deposition of calcium in various tissues throughout the body. These conditions can affect multiple organs, including the heart, kidneys, and lungs, and can lead to serious complications such as heart failure, kidney failure, and pulmonary hypertension.
Despite their prevalence and severity, there are currently no effective treatments for calcification disorders. Existing therapies only manage symptoms or slow disease progression but do not address the underlying cause of calcification.
This is where Sanifit comes in. The company's approach is based on a deep understanding of the molecular mechanisms involved in calcification disorders. Sanifit's research has identified specific proteins that play key roles in regulating calcium deposition in tissues.
Using this knowledge, Sanifit has developed a pipeline of novel drug candidates that target these proteins with high specificity and potency. These drugs have shown promising results in preclinical studies and are now being evaluated in clinical trials.
One such drug candidate is SNF472, which targets an enzyme called TNAP (tissue-nonspecific alkaline phosphatase) that plays a critical role in regulating calcium deposition. SNF472 has been shown to reduce vascular calcification and improve cardiovascular outcomes in patients with end-stage renal disease (ESRD).
Another drug candidate is SNF801, which targets another protein involved in regulating calcium deposition called ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1). Preclinical studies have shown that SNF801 can prevent arterial calcification without affecting bone mineralization.
In addition to its drug development efforts, Sanifit also conducts research into other aspects of calcification disorders such as biomarkers and diagnostic tools. This holistic approach allows Sanifit to better understand these complex diseases and develop more effective treatments.
Sanifit's commitment to innovation has earned it recognition from both industry peers and investors alike. In 2019 alone, Sanifit raised €55 million ($61 million) through a series D funding round led by Caixa Capital Risc along with participation from new investors Columbus Venture Partners Healthtech Fund II FCRE CRB Inverbío II Innvierte Biotech II FCR; Alta Life Sciences; CDTI Innvierte Economía Sostenible F.C.R.; Asabys Partners I FCR; Gilde Healthcare III Fund B.V.; Lundbeckfonden Ventures A/S; Ysios Capital Partners SGEIC SAU; Forbion Capital Partners V Coöperatief U.A., among others
In conclusion,
Sanifit represents an exciting new approach to treating calcification disorders using innovative drugs targeting specific proteins involved in regulating calcium deposition rather than just managing symptoms or slowing disease progression like existing therapies do today . With its deep understanding of molecular mechanisms behind these complex diseases combined with cutting-edge technology , it promises hope for millions suffering from this debilitating condition worldwide .